These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hair loss induced by dopamine agonist: case report and review of the literature. Miwa H; Kondo T Parkinsonism Relat Disord; 2003 Oct; 10(1):51-2. PubMed ID: 14499208 [TBL] [Abstract][Full Text] [Related]
5. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups]. Lökk J Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806 [No Abstract] [Full Text] [Related]
6. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Senol MG; Togrol RE Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893 [No Abstract] [Full Text] [Related]
7. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks? Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763 [No Abstract] [Full Text] [Related]
8. Adverse drug reaction suggested by a clinical vignette. Finestone AJ Clin Interv Aging; 2011; 6():199. PubMed ID: 21822375 [No Abstract] [Full Text] [Related]
9. Alopecia induced by dopamine agonists. Tabamo RE; Di Rocco A Neurology; 2002 Mar; 58(5):829-30. PubMed ID: 11889256 [No Abstract] [Full Text] [Related]
10. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Linazasoro G; Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487 [TBL] [Abstract][Full Text] [Related]
11. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent. Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828 [No Abstract] [Full Text] [Related]
12. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients]. Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610 [TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists and the risk of cardiac-valve regurgitation. Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453 [TBL] [Abstract][Full Text] [Related]
14. Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists. Del Dotto P; Gambaccini G; Caneparo D; Berti C; Bernardini S; Bonuccelli U Neurol Sci; 2003 Oct; 24(3):170-1. PubMed ID: 14598071 [TBL] [Abstract][Full Text] [Related]
15. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285 [TBL] [Abstract][Full Text] [Related]
16. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Ling LH; Ahlskog JE; Munger TM; Limper AH; Oh JK Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467 [TBL] [Abstract][Full Text] [Related]
17. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study. Utsumi H; Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474 [TBL] [Abstract][Full Text] [Related]
18. [Pathological gambling induced by dopamine agonists]. Gahr M; Connemann BJ; Schönfeldt-Lecuona CJ Fortschr Neurol Psychiatr; 2011 Aug; 79(8):470-4. PubMed ID: 21809260 [TBL] [Abstract][Full Text] [Related]